newsfilter
← Earnings
Earnings Releases·

Retension Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Reported a net loss of $5.9 million for the third quarter ended September 30, 2026, compared to a net loss of $1.5 million for the same period in 2025.
    • Research and development expenses totaled $5.0 million for the quarter, an increase from $1.4 million in the third quarter of 2025, driven primarily by Phase 2b clinical trial costs.
    • General and administrative expenses were $1.0 million for the quarter, up from $0.3 million in the third quarter of 2025, primarily due to higher personnel costs.
    • Cash and cash equivalents were $9.2 million as of September 30, 2026, down from $18.9 million as of December 31, 2025.
    • Pro forma cash and cash equivalents as of September 30, 2026, including net IPO proceeds of approximately $45.1 million, were approximately $54.3 million.
    • Total operating expenses for the nine months ended September 30, 2026, were $13.8 million, compared to $3.8 million for the same period in 2025.
    • Net loss for the nine months ended September 30, 2026, was $13.4 million, compared to $3.4 million for the same period in 2025.
    • Net loss per share (basic and diluted) was $(7.33) for the three months ended September 30, 2026, compared to $(1.83) in the prior year period.
  • Guidance and Future Outlook:

    • Topline data from the Phase 2b clinical trial of RTN-001 is expected in the first half of 2027.
    • The Phase 2b trial results will inform dose selection for the upcoming Phase 3 trial.
    • Management remains focused on executing the Phase 2b trial to bring a new treatment option to patients with uncontrolled and resistant hypertension.
  • Business Segments and Product Lines:

    • The company is a clinical-stage biopharmaceutical firm focused on developing medicines for hypertension and other cardiovascular diseases.
    • Lead candidate RTN-001 is a next-generation PDE5 inhibitor designed to enhance nitric oxide signaling in central arteries.
    • RTN-001 has been studied in multiple clinical trials totaling 265 subjects, demonstrating efficacy and safety with clinically meaningful blood pressure reductions.
    • RTN-001 is being developed under an exclusive worldwide license from Sanofi S.A.
    • The Phase 2b trial is a randomized, placebo-controlled, dose-ranging study evaluating RTN-001 in approximately 280 patients with uncontrolled hypertension.
  • Market and Competitive Landscape:

    • RTN-001 targets uncontrolled and resistant hypertension, a condition affecting approximately 30 million Americans.
    • The company aims to address a core driver of hypertension by targeting central arteries not adequately reached by first-generation PDE5 inhibitors.
  • Risks and Challenges:

    • The press release notes that actual results may differ materially from forward-looking statements due to uncertainties, risks, and assumptions, including those described in the Company's final prospectus and Form 10-Q.
    • Specific risks include the timing, design, and results of the Phase 2b clinical trial and the Company's expected cash runway.
  • Management Commentary and Tone:

    • CEO Eric Keller stated that completing the IPO was an important step providing capital to complete the Phase 2b trial and prepare for Phase 3.
    • Management highlighted the formation of a leadership team with deep experience in advancing cardiovascular and metabolic therapies from clinical development through approval.
    • A Scientific Advisory Board of leading investigators in hypertension, cardiology, and nephrology has been formed.
  • Other Key Points:

    • Completed an upsized initial public offering in October 2026, selling 4,312,500 shares at $12.00 per share, including the full exercise of the underwriters' option.
    • The IPO generated gross proceeds of $51.75 million and net proceeds of approximately $45.1 million.
    • Common stock began trading on the Nasdaq Capital Market under the ticker symbol "RTSN" on October 9, 2026.
    • Strengthened the executive leadership team with new appointments including Chief Medical Officer Alison D. Schecter, CFO Alex Schwartz, EVP LeAnne Bloedon, VP Kevin Schutz, and VP Robert Wong.
    • Added Pavan Cheruvu, M.D., to the Board of Directors.
    • Formed a Scientific Advisory Board including Omar Al Dhaybi, James L. Januzzi, Luke J. Laffin, Ian Wilkinson, and Randall M. Zusman.
Company
RETENSION PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology